Implementation science, the study of turning scientific discoveries into everyday practices, has become crucial in healthcare, particularly in resource-constrained South Africa, home to the world's largest HIV epidemic. Saiqa Mullick, director of implementation science at Wits RHI, is a leading practitioner in this field. With a background in science and a passion for art, Mullick leads a team that works to make HIV prevention accessible and effective.

Mullick's journey in implementation science began in 2014 when she established the Wits RHI Implementation Science Directorate with just one other staff member. Over the years, her team has grown to 600 people, although US funding cuts have reduced the number to around 200. Despite this, the Directorate's reputation has never been higher, thanks in part to Mullick's work on studies like Len4PrEP, which aims to roll out lenacapavir, a six-monthly injection that prevents HIV.

Lenacapavir, also known as LEN, is a game-changer in HIV prevention, with a nearly foolproof track record in preventing HIV transmission. Mullick's study, Len4PrEP, explores how best to introduce LEN at government clinics, providing an additional choice for those seeking HIV prevention. The study has already yielded significant findings, including that 86% of clients prefer the LEN injection over the daily pill.

Mullick's work emphasizes the importance of choice in HIV prevention. She notes that people want options in pre-exposure prophylaxis (PrEP), including service delivery and injection sites. Her team's research has also revealed that men are more likely to opt for LEN, while women prefer injections in the buttock. These insights can make a significant difference in the effectiveness of HIV prevention programs.

Born in Nairobi, Kenya, Mullick comes from a family of high achievers. Her grandparents emigrated to Kenya in the early 1900s, and her parents instilled in her a strong work ethic. Her mother, a doctor, and her father, an engineer, encouraged Mullick and her sisters to pursue their education and careers. Mullick's accent, which she describes as "unmistakably British," reflects her upbringing.

Mullick's personal life reflects her passion for art and design. She enjoys taking pictures of architecture and beautiful art, which she finds helps her decompress. Her office, with its minimalist decor and single peace lily, reflects her love of simplicity and order. Despite her busy schedule, Mullick prioritizes her work and takes pride in her team's accomplishments.

As Mullick continues to lead the implementation science team at Wits RHI, her work will be crucial in shaping the future of HIV prevention in South Africa. With her team's help, she aims to make HIV science accessible and effective, ultimately reducing the country's HIV epidemic. The study's findings will inform the early roll-out of LEN, providing a new option for those seeking HIV prevention.

Key points

  • Mullick's work focuses on implementation science, which turns scientific discoveries into everyday practices.
  • The Len4PrEP study explores how best to introduce lenacapavir, a six-monthly injection that prevents HIV.
  • Mullick emphasizes the importance of choice in HIV prevention, including service delivery and injection sites.

Reporting sources

Share this story

Written by

SaharaWire Newsroom
SaharaWire

Reporting for SaharaWire from the Nairobi bureau.